Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SENS logo SENS
Upturn stock ratingUpturn stock rating
SENS logo

Senseonics Holdings Inc (SENS)

Upturn stock ratingUpturn stock rating
$0.5
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/11/2025: SENS (5-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Outstanding Performance

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $1.55

1 Year Target Price $1.55

Analysts Price Target For last 52 week
$1.55 Target price
52w Low $0.25
Current$0.5
52w High $1.4

Analysis of Past Performance

Type Stock
Historic Profit 57.77%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/11/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 402.40M USD
Price to earnings Ratio -
1Y Target Price 1.55
Price to earnings Ratio -
1Y Target Price 1.55
Volume (30-day avg) 4
Beta 0.99
52 Weeks Range 0.25 - 1.40
Updated Date 07/13/2025
52 Weeks Range 0.25 - 1.40
Updated Date 07/13/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.11

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -215.57%

Management Effectiveness

Return on Assets (TTM) -41%
Return on Equity (TTM) -161.19%

Valuation

Trailing PE -
Forward PE 21.51
Enterprise Value 379242708
Price to Sales(TTM) 16.99
Enterprise Value 379242708
Price to Sales(TTM) 16.99
Enterprise Value to Revenue 16.01
Enterprise Value to EBITDA 1.76
Shares Outstanding 809830016
Shares Floating 599788651
Shares Outstanding 809830016
Shares Floating 599788651
Percent Insiders 8.89
Percent Institutions 10.96

ai summary icon Upturn AI SWOT

Senseonics Holdings Inc

stock logo

Company Overview

overview logo History and Background

Senseonics Holdings, Inc. was founded in 2003. It focuses on the design, development, and commercialization of glucose monitoring systems, primarily continuous glucose monitoring (CGM) systems for people with diabetes. Its initial focus was on developing long-term implantable CGM systems. Over the years, it has achieved FDA approvals for its Eversense and Eversense E3 systems.

business area logo Core Business Areas

  • Continuous Glucose Monitoring (CGM) Systems: The core of Senseonics' business is the development and sale of its Eversense CGM systems, which include an implantable sensor, a smart transmitter, and a mobile app for data monitoring.

leadership logo Leadership and Structure

The company has a leadership team including a CEO, CFO, and other key executives responsible for different aspects of the business such as research and development, sales, and marketing. The organizational structure typically involves departments for research, product development, sales, marketing, regulatory affairs, and finance.

Top Products and Market Share

overview logo Key Offerings

  • Eversense CGM System: The Eversense CGM System features a small sensor implanted under the skin that measures glucose levels continuously for up to 180 days (Eversense) or 365 days (Eversense E3), depending on the specific version. The system also includes a smart transmitter worn on the arm and a mobile app for real-time glucose monitoring and alerts. Market share data is volatile but typically ranges between 1-3% of the total CGM market. Competitors include Dexcom (DXCM) and Abbott Laboratories (ABT) which have the FreeStyle Libre line.
  • Eversense E3 CGM System: The next-generation implantable CGM system with sensor life up to 365 days. This system offers the same functionality as the original Eversense system with a longer sensor life. Market share is included within the overall Eversense CGM numbers. Competitors include Dexcom (DXCM) and Abbott Laboratories (ABT) which have the FreeStyle Libre line.

Market Dynamics

industry overview logo Industry Overview

The glucose monitoring market is driven by the increasing prevalence of diabetes, technological advancements in CGM systems, and growing patient demand for more convenient and accurate monitoring solutions. The industry is highly competitive, with established players and emerging companies vying for market share.

Positioning

Senseonics is positioned as a provider of long-term implantable CGM systems, differentiating itself from competitors offering traditional CGM systems that require frequent sensor replacements. Its competitive advantage lies in the convenience of long-term monitoring and reduced insertion frequency.

Total Addressable Market (TAM)

The global CGM market is expected to reach tens of billions of USD within the next 5-7 years. Senseonics is attempting to carve out a share of this market with its long term and next generation technologies.

Upturn SWOT Analysis

Strengths

  • Long-term implantable sensor
  • Reduced insertion frequency
  • Potential for improved patient adherence
  • Proprietary technology

Weaknesses

  • Higher initial cost
  • Surgical insertion required
  • Reliance on partner (Ascensia) for distribution and sales
  • Limited market share compared to competitors

Opportunities

  • Expanding partnerships
  • Further technological advancements in sensor life and accuracy
  • Increased adoption of CGM systems
  • Potential for use in non-diabetic populations

Threats

  • Competition from established CGM providers (Dexcom, Abbott)
  • Reimbursement challenges
  • Potential for adverse events related to sensor implantation
  • Technological disruption from new glucose monitoring methods

Competitors and Market Share

competitor logo Key Competitors

  • DXCM
  • ABT

Competitive Landscape

Senseonics' long-term implantable sensor provides a competitive advantage over traditional CGM systems. However, it faces challenges from established players with greater market share and resources. Success depends on driving adoption, securing reimbursement, and demonstrating the clinical benefits of its technology.

Growth Trajectory and Initiatives

Historical Growth: Senseonics' historical growth has been characterized by periods of rapid expansion followed by periods of market adoption challenges. Reimbursement and sales execution have impacted growth.

Future Projections: Future growth projections are uncertain and depend on factors such as regulatory approvals, market adoption, and competition. Consult analyst reports for revenue estimates.

Recent Initiatives: Recent initiatives include partnerships with Ascensia Diabetes Care for commercialization, advancements in sensor technology (e.g., Eversense E3), and efforts to expand market access through reimbursement coverage.

Summary

Senseonics offers a unique long-term implantable CGM system that differentiates it from competitors. While its technology is innovative, it faces challenges related to market adoption, reimbursement, and competition. Successful execution of its commercialization strategy and continued technological advancements are crucial for future growth. Recent initiatives with Ascensia Diabetes Care could prove beneficial. Investors should monitor the company's progress in securing reimbursement coverage and driving sales growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. Financial data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Senseonics Holdings Inc

Exchange NYSE MKT
Headquaters Germantown, MD, United States
IPO Launch date 2016-03-17
President, CEO & Director Dr. Timothy T. Goodnow Ph.D.
Sector Healthcare
Industry Medical Devices
Full time employees 117
Full time employees 117

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.